TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37138751

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) program
Number of subjects: 340

Group type: COMPARATOR
Intervention: Conventional perioperative care programs
Number of subjects: 340
Study: 37138800

Group type: EXPERIMENTAL
Intervention: Doraya catheter
Number of subjects: 9
Study: 37139076

Group type: EXPERIMENTAL
Intervention: Verticalization at 0°, -5°, 15°, 30°, 45°, and 70° using a standardized Sara Combilizer chair for 3-5 minutes each.
Number of subjects: 20
Study: 37139182

Group type: EXPERIMENTAL
Intervention: General Anxiety Disorder 7-Item (GAD-7) scale
Number of subjects: 200
Study: 37139325

Group type: EXPERIMENTAL
Intervention: Pranayama-assisted TF-CBT
Number of subjects: 74

Group type: COMPARATOR
Intervention: TF-CBT alone
Number of subjects: 74
Study: 37139536

Group type: EXPERIMENTAL
Intervention: Amphetamine use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37139665

Group type: EXPERIMENTAL
Intervention: Neoadjuvant modified FOLFIRINOX (mFOLFIRINOX)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Post-operative plasma ctDNA analysis
Number of subjects: 44
Study: 37139775

Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy (80 hours) and bimanual intensive therapy (20 hours)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bimanual intensive therapy (80 hours) and modified constraint-induced movement therapy (20 hours)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Modified constraint-induced movement therapy (20 hours)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy (80 hours)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bimanual intensive therapy (20 hours)
Number of subjects: 21
Study: 37139814

Group type: EXPERIMENTAL
Intervention: ICAS (intracranial atherosclerotic stenosis)
Number of subjects: 3949

Group type: COMPARATOR
Intervention: No ICAS
Number of subjects: 3949

Group type: EXPERIMENTAL
Intervention: ICAS
Number of subjects: 3949
Study: 37139817

Group type: EXPERIMENTAL
Intervention: Transuterine Ultrasound-Guided Fetal Embolization
Number of subjects: 0
Study: 37139815

Group type: EXPERIMENTAL
Intervention: 2-month educational intervention comprising a stroke video and riskometer app
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1-time counseling (Control)
Number of subjects: 100
Study: 37139855

Group type: COMPARATOR
Intervention: Early peripheral sensory dysfunction (EPSD) identified through quantitative sensory testing (QST) in individuals without T2DM.
Number of subjects: 225

Group type: COMPARATOR
Intervention: Metabolic syndrome in individuals with T2DM.
Number of subjects: 225

Group type: COMPARATOR
Intervention: Skin advanced glycation end-products (AGEs) in individuals with T2DM.
Number of subjects: 225

Group type: COMPARATOR
Intervention: T2DM and EPSD in longitudinal analysis.
Number of subjects: 225

Group type: COMPARATOR
Intervention: EPSD in longitudinal analysis.
Number of subjects: 225

Group type: COMPARATOR
Intervention: Sensory loss phenotype associated with EPSD.
Number of subjects: 225
Study: 37139963

Group type: EXPERIMENTAL
Intervention: Toripalimab in combination with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other first-choice drugs
Number of subjects: 0
Study: 37140175

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 154
Study: 37140395

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Gastric banding
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 1351
Study: 37140460

Group type: EXPERIMENTAL
Intervention: e-CBT and treatment as usual (TAU)
Number of subjects: 170

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 170
Study: 37140493

Group type: EXPERIMENTAL
Intervention: Buprenorphine administration initiated by practitioners
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30-day treatment engagement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Attendance at treatment visits
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Self-reported overdose events
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ED clinician readiness
Number of subjects: 40
Study: 37140517

Group type: EXPERIMENTAL
Intervention: 1:10,000-diluted topical epinephrine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 66
Study: 37140539

Group type: EXPERIMENTAL
Intervention: Etanercept (0.8 mg/kg weekly; maximum 50 mg)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Etanercept (active treatment)
Number of subjects: 127
Study: 37140558

Group type: EXPERIMENTAL
Intervention: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 15/15 μg of GI.1/GII.4c genotype VLPs
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 15/50 μg of GI.1/GII.4c genotype VLPs
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 50/50 μg of GI.1/GII.4c genotype VLPs
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) with 50/150 μg of GI.1/GII.4c genotype VLPs
Number of subjects: 240
Study: 37140602

Group type: EXPERIMENTAL
Intervention: BI 836880 monotherapy (720 mg Q3W)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BI 836880 (720 mg Q3W) plus ezabenlimab (240 mg Q3W)
Number of subjects: 21
Study: 37140705

Group type: EXPERIMENTAL
Intervention: Vedolizumab (3 doses during induction phase)
Number of subjects: 268
Study: 37140727

Group type: EXPERIMENTAL
Intervention: Cotadutide (single dose)
Number of subjects: 37
Study: 37140896

Group type: EXPERIMENTAL
Intervention: Subretinal transplantation of neural progenitors derived from human embryonic stem cells
Number of subjects: 0
Study: 37140904

Group type: EXPERIMENTAL
Intervention: Bacterial decolonization (BD) using intranasal mupirocin ointment twice daily and chlorhexidine body cleanser once daily for 5 days prior to RT and repeated for 5 days every 2 weeks through RT.
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard of care (control group).
Number of subjects: 77
Study: 37141002

Group type: EXPERIMENTAL
Intervention: Cervical red light/near-infrared-emitting collar (combined: 660 nm, 740 nm, 810 nm, and 870 nm)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both active and sham users
Number of subjects: 30
Study: 37141005

Group type: EXPERIMENTAL
Intervention: Peer-led Facebook groups
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Professionally-guided Facebook groups
Number of subjects: 119

Group type: COMPARATOR
Intervention: Both group types
Number of subjects: 119
Study: 37141032

Group type: EXPERIMENTAL
Intervention: 2GETHER intervention (five-session hybrid group- and couple-based intervention delivered via videoconference)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (single-session HIV testing and risk reduction counseling protocol)
Number of subjects: 200
Study: 37141036

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General Health Education (GHE)
Number of subjects: 100
Study: 37141073

Group type: EXPERIMENTAL
Intervention: EUS-GBD
Number of subjects: 139

Group type: COMPARATOR
Intervention: PT-GBD
Number of subjects: 139
Study: 37141104

Group type: EXPERIMENTAL
Intervention: Water exchange (WE) with warm water
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Water exchange (WE) with 25% saline
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Water exchange (WE) with 50% saline
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: 25% saline
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: 50% saline
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Water infusion
Number of subjects: 296
Study: 37141225

Group type: EXPERIMENTAL
Intervention: Behavioral-education intervention (8 sessions over 12 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (dialysis education alone)
Number of subjects: 45
Study: 37141237

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) delivered with a tissue reflectance sensor; 5 cycles of ischemia/reperfusion in the non-paralyzed upper limb.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham control with cuff pressure at 30 mmHg for 5 minutes.
Number of subjects: 51
Study: 37141260

Group type: EXPERIMENTAL
Intervention: Home-based inspiratory muscle training (IMT) using 30% of maximal inspiratory pressure, increasing by 10% weekly, 30 repetitions, twice a day for 6 weeks.
Number of subjects: 10

Group type: COMPARATOR
Intervention: SHAM (IMT without load)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Home-based inspiratory muscle training (IMT)
Number of subjects: 10
Study: 37141291

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy with lymph nodes station 10-11-12-13-14 sampling
Number of subjects: 0
Study: 37141294

Group type: EXPERIMENTAL
Intervention: pembrolizumab 2 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: docetaxel 75 mg/m²
Number of subjects: 0
Study: 37141538

Group type: EXPERIMENTAL
Intervention: Pancreatic cancer screening using endoscopic ultrasound and/or magnetic resonance cholangiopancreatography
Number of subjects: 252
Study: 37141544

Group type: EXPERIMENTAL
Intervention: Nivolumab plus platinum-doublet chemotherapy
Number of subjects: 358

Group type: COMPARATOR
Intervention: Platinum-doublet chemotherapy alone
Number of subjects: 358
Study: 37141601

Group type: EXPERIMENTAL
Intervention: Multimedia Educational Tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37141764

Group type: EXPERIMENTAL
Intervention: GLYT1 inhibitor (PF-03463275) 40 or 60 mg twice daily with cognitive training (CT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Cognitive training (CT) alone
Number of subjects: 71
Study: 37141828

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for ≤35 cycles
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Second-course pembrolizumab after disease progression
Number of subjects: 124
Study: 37141847

Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg every 2 weeks (Q2W) and axitinib 5 mg orally two times daily
Number of subjects: 61
Study: 37142055

Group type: EXPERIMENTAL
Intervention: Femoral nerve blockade (FNB) with 1% lidocaine with adrenaline
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo FNB with 0.9% saline
Number of subjects: 80
Study: 37142075

Group type: EXPERIMENTAL
Intervention: Hysteroscopic resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultrasound-guided dilation and evacuation
Number of subjects: 0
Study: 37142092

Group type: EXPERIMENTAL
Intervention: Clinician-facing electronic health record prompts and an EHR-integrated everyday shared decision-making tool
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Preintervention phase
Number of subjects: 1090
Study: 37142177

Group type: EXPERIMENTAL
Intervention: TIPS intervention (web-based training for parenting strategies after child brain injury)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual-care control (TAU)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: TIPS intervention
Number of subjects: 83
Study: 37142273

Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 45049

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 45049

Group type: COMPARATOR
Intervention: Cytisine vs Varenicline
Number of subjects: 45049
Study: 37142291

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 0
Study: 37142308

Group type: EXPERIMENTAL
Intervention: Psilocybin (15 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Psilocybin (15 mg and 25 mg) with psychotherapy
Number of subjects: 15
Study: 37142317

Group type: EXPERIMENTAL
Intervention: Holistic needs assessment (HNA)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 147
Study: 37142335

Group type: EXPERIMENTAL
Intervention: Maternal lipid-based nutrient supplement initiated preconceptionally (arm 1, n=217)
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Maternal lipid-based nutrient supplement initiated at 12 weeks gestation (arm 2, n=230)
Number of subjects: 667

Group type: COMPARATOR
Intervention: No maternal nutrition supplementation (arm 3, n=220)
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: All intervention arms combined
Number of subjects: 667
Study: 37142372

Group type: EXPERIMENTAL
Intervention: Tucatinib plus trastuzumab (cohort A and B)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Tucatinib monotherapy (cohort C)
Number of subjects: 117
Study: 37142373

Group type: EXPERIMENTAL
Intervention: LIPU-MB with intravenous albumin-bound paclitaxel infusion every 3 weeks for up to six cycles (dose levels 1 to 5: 40-215 mg/m²)
Number of subjects: 17
Study: 37142371

Group type: EXPERIMENTAL
Intervention: Standard of care plus abiraterone (n=501)
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Standard of care plus abiraterone and enzalutamide (n=462)
Number of subjects: 1919

Group type: COMPARATOR
Intervention: Standard of care (n=502 in abiraterone trial; n=454 in abiraterone and enzalutamide trial)
Number of subjects: 1919
Study: 37142383

Group type: EXPERIMENTAL
Intervention: Reduced frequency pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (not explicitly mentioned)
Number of subjects: 0
Study: 37142388

Group type: EXPERIMENTAL
Intervention: High oxygenation (91-95% SpO2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low oxygenation (85-89% SpO2)
Number of subjects: 20
Study: 37142418

Group type: EXPERIMENTAL
Intervention: CoolSource cooling vest
Number of subjects: 30
Study: 37142474

Group type: EXPERIMENTAL
Intervention: Average daily opioid dose in morphine milligram equivalents (MME)
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: Number of distinct prescribers visited
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: Number of distinct pharmacies visited
Number of subjects: 1421
Study: 37142543

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (standard treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene addition therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genome editing using CRISPR-Cas9 nuclease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell generation from induced pluripotent stem cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRNA therapeutics
Number of subjects: 0
Study: 37142551

Group type: EXPERIMENTAL
Intervention: WHO 2015 definition for RSV-LRTI
Number of subjects: 2401

Group type: EXPERIMENTAL
Intervention: Alternative case definitions for RSV-LRTI
Number of subjects: 2401

Group type: EXPERIMENTAL
Intervention: WHO 2015 definition for severe RSV-LRTI
Number of subjects: 2401

Group type: COMPARATOR
Intervention: LRTI/bronchiolitis/pneumonia cases clinically diagnosed by nonstudy physicians
Number of subjects: 2401
Study: 37142730

Group type: EXPERIMENTAL
Intervention: Gemcitabine-based treatment (n=99)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine treatment
Number of subjects: 139
Study: 37142733

Group type: EXPERIMENTAL
Intervention: Single dose antibiotic (IIIrd gen cephalosporin) administered within 30-min of POEM
Number of subjects: 114

Group type: COMPARATOR
Intervention: Multiple dose antibiotic (IIIrd gen cephalosporin) administered for a total of three days
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Single dose antibiotic (IIIrd gen cephalosporin)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Multiple dose antibiotic (IIIrd gen cephalosporin)
Number of subjects: 114
Study: 37142763

Group type: EXPERIMENTAL
Intervention: 300 mg dupilumab subcutaneously every 2 weeks for 24 weeks
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo subcutaneously every 2 weeks for 24 weeks
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: 300 mg dupilumab
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 37142762

Group type: EXPERIMENTAL
Intervention: Banff Automation System
Number of subjects: 3054
Study: 37142988

Group type: EXPERIMENTAL
Intervention: Tap water drinking
Number of subjects: 29584

Group type: COMPARATOR
Intervention: Control (non-tap water drinking)
Number of subjects: 29584
Study: 37143003

Group type: EXPERIMENTAL
Intervention: Blended Forensic Outpatient Systemic Therapy (FASTb)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Regular Forensic Outpatient Systemic Therapy (FASTr)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both FASTb and FASTr
Number of subjects: 200
Study: 37143029

Group type: EXPERIMENTAL
Intervention: Home-based HBV screening
Number of subjects: 0
Study: 37143040

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg/day)
Number of subjects: 86
Study: 37143072

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention based on temporal patterns of falls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (before intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Number of subjects: 0
Study: 37143108

Group type: EXPERIMENTAL
Intervention: Patient-derived organoids and in-vitro sensitivity testing
Number of subjects: 90
Study: 37143128

Group type: EXPERIMENTAL
Intervention: Single application of selective serotonin reuptake inhibitor (SSRI) or serotonin-noradrenaline reuptake inhibitor (SNRI)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: SSRI/SNRI combined with mood stabilizer
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: SSRI/SNRI combined with quetiapine (≥ 150 mg/day)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Follow-up until 4 years or switching to BD
Number of subjects: 480
Study: 37143131

Group type: EXPERIMENTAL
Intervention: Organizational Readiness to Change Assessment (ORCA) tool - context domain
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Organizational Readiness to Change Assessment (ORCA) tool - facility resources
Number of subjects: 59
Study: 37143154

Group type: EXPERIMENTAL
Intervention: MR-guided online adaptive radiotherapy (RT) with concurrent chemotherapy, conventionally fractioned RT with isotoxic dose escalation up to 70 Gy, online plan adaptation performed once weekly or in case of major anatomical changes.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MR-guided online adaptive radiotherapy (RT) with concurrent chemotherapy.
Number of subjects: 30
Study: 37143158

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) followed by surgery within 24 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment (surgery followed by conventional radiotherapy after 1-2 weeks)
Number of subjects: 100
Study: 37143199

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 0
Study: 37143408

Group type: EXPERIMENTAL
Intervention: Physiotherapy competencies for management of nociplastic pain
Number of subjects: 23
Study: 37143685

Group type: EXPERIMENTAL
Intervention: Ruxolitinib plus simvastatin (5 mg BID for 7 days followed by 10 mg BID for 7 days and 40 mg once a day for 14 days)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cytokine profiling
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Supervised Machine Learning analysis
Number of subjects: 92
Study: 37143955

Group type: EXPERIMENTAL
Intervention: Glyaderm®
Number of subjects: 66

Group type: COMPARATOR
Intervention: STSG
Number of subjects: 66
Study: 37143998

Group type: EXPERIMENTAL
Intervention: PACAP infusion for 20 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VIP infusion for 20 min
Number of subjects: 0
Study: 37143999

Group type: EXPERIMENTAL
Intervention: Intra-arterial TNK (4 mg) followed by TNK (0.4 mg/min for 20 min) during EVT
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (historical cohort)
Number of subjects: 26
Study: 37144003

Group type: EXPERIMENTAL
Intervention: Education program (individual and group sessions over a 6-weeks period)
Number of subjects: 120
Study: 37144109

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3708

Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 3708
Study: 37144150

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Warming phase post-therapeutic hypothermia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Neonatal controls (no hypothermia)
Number of subjects: 100
Study: 37144153

Group type: EXPERIMENTAL
Intervention: Own Mother's Milk (OMM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Donor Human Milk (DHM)
Number of subjects: 0
Study: 37144470

Group type: EXPERIMENTAL
Intervention: Sound levels measured continuously using a Gravity Sound Level Meter.
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Light levels measured continuously using an Adafruit TSL2561 digital luminosity sensor.
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Sound and light monitoring across different times of the day.
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Monitoring of sound and light events during weekdays and weekends.
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Analysis of alarm frequencies in the ICU.
Number of subjects: 136
Study: 37144478

Group type: EXPERIMENTAL
Intervention: Women’s suggestions on improving maternal and newborn care during facility-based birth in Italy during the COVID-19 pandemic.
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Word co-occurrence network (WCON) analysis of women's responses.
Number of subjects: 2010
Study: 37144634

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.14 g·kg -1 ·d -1)
Number of subjects: 237
Study: 37144678

Group type: EXPERIMENTAL
Intervention: Trained surgeons
Number of subjects: 8

Group type: COMPARATOR
Intervention: Self-taught surgeons
Number of subjects: 8